Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Safety and Pharmacokinetics of LP002 (a Humanized Monoclonal Antibody Targeting PD-L1) in Patients With Malignant Digestive System Neoplasms

NCT04755543 is registered in ClinicalTrials.gov with Taizhou HoudeAoke Biomedical Co., Ltd. as lead sponsor.

NCT NCT04755543
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04755543 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Safety and Pharmacokinetics of LP002 (a Humanized Monoclonal Antibody Targeting PD-L1) in Patients With Malignant Digestive System Neoplasms
Lead sponsor
Taizhou HoudeAoke Biomedical Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
June 17, 2019
Completion date
June 30, 2022
Enrollment
94 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

digestive system neoplasms